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How Does a Physician Avoid Prescribing
Drugs and Medical Procedures
That Have Reproductive
and Developmental Risks?
Robert L. Brent, MD, PhD, DSc (Hon)
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In 1967 I published an article titled the ‘‘Medicolegal Aspects of Teratology’’ in which I predicted the epidemic in malpractice litigation. This speculation was based on an inﬂux of requests to evaluate the merits of what
I characterized as nonmeritorious malpractice cases involving birth defects [1]. Even in the 1960s teratologists were aware that only a small percentage of birth defects were caused by drugs, chemicals, and physical agents
[2–8]. In 2007 even more information is available to conﬁrm this viewpoint
(Table 1) [9–11]. Birth defects caused by drugs, chemicals, and physical
agents account for a very small percentage of birth defects (see Table 1).
In the United States the medicolegal climate has changed considerably in
the past 50 years. When I was appointed to the faculty at the Jeﬀerson Medical College in Philadelphia in 1957, my malpractice premium was $50.00
per year. I am certain it is hard for many young obstetricians and perinatologists to believe that fact. But the climate has changed dramatically. Two
reports of congenital malformations can put a historical perspective on
the present malpractice climate in the United States.
The philosophy of some members of the legal profession and of the public is that someone must be responsible for personal damages that have been
incurred. Historically, the father or mother of a malformed infant was open
to ridicule, criticism, or even persecution [12–14]. Folklore and superstition
dominated the ﬁeld, and the causes of malformations were attributed to evil
spirits, fornication with animals, lewd thoughts, or other immoral acts. Certainly, in the 1600s no one could have thought of receiving compensation for
the birth of a malformed child. The following case presentation highlights
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Table 1
Causes of human congenital malformations observed during the ﬁrst year of life
Suspected cause

Percentage of total

Unknown
Polygenic
Multifactorial (gene–environment interactions)
Spontaneous errors of development
Synergistic interactions of teratogens
Genetic
Autosomal and sex-linked inherited genetic disease
Cytogenetic (chromosomal abnormalities)
New mutations
Environmental
Maternal conditions: alcoholism; diabetes; endocrinopathies;
phenylketonuria; smoking and nicotine; starvation; nutritional deﬁcits
Infectious agents: rubella, toxoplasmosis, syphilis, herpes simplex,
cytomegalovirus, varicella-zoster, Venezuelan equine encephalitis,
parvovirus B19
Mechanical problems (deformations): amniotic band constrictions;
umbilical cord constraint; disparity in uterine size and uterine
contents
Chemicals, prescription drugs, high-dose ionizing radiation,
hyperthermia

65–75
d
d
d
d
15–25
d
d
d
10
4
3

1–2

!1

Data from Brent RL. Utilization of developmental basic science principles in the evaluation of
reproductive risks from pre- and postconception environmental radiation exposures. Teratology
1999;59:182–4.

the ignorance and superstition that surrounded the birth of a malformed oﬀspring in the seventeenth century:
At a General Court held at New Haven on March 2, 1641, it transpired
that on the preceding February 14,
John Wakeman a planter and member of this church acquainted the magistrates that a sow of his which he had lately bought of Henry Browning,
then with pigge, had now brought among divers liveing and rightly shaped
pigs, one prodigious monster, which he then brought with him to be viewed
and considered. The monster was come to the full growth as the other piggs
for ought could be discerned, butt brought forth dead. Itt had no haire on
the whole body, the skin was very tender and a reddish white collour like
a childs; the head most straing, itt had butt one eye in the middle of the
face, and thatt large an open, like some blemished eye of a man; over the
eye the bottome of the foreheade which was like a childes, a thing of ﬂesh
grew forth and hung downe, itt was hollow, and like a man’s instrument of
generation. A nose, mouth and chinne deformed, butt nott much unlike
a childs the neck and eares had also such resemblance.

This description is that of a typical cyclopean monster. The record
continues,
[A] strange impression was allso upon many that saw the monster, (therein
guided by the neare resemblance of the eye) that one George Spencer, late
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servant to the said Henry Browning, had beene actor in unnatureall and
abominable ﬁlthynes with the sow–.

(It came out during the proceedings that Spencer actually had not been in
the service of Browning at the critical time!)
The aforementioned George Spencer so suspected hath butt one eye for use,
the other hath (as itt is called) a pearle in itt, is whitishy Y deformed, and
his deformed eye being beheld and compared together with the eye of the
monster, seamed to be as like as the eye in the glass to the eye in the face.

There is little doubt that George Spencer had a cataract in one eye. That
he ‘‘had beene formerly notorious in the plantation for a prophane, lying
scoﬃng and lewd speritt’’ surely did not help his situation.
Although professing innocence, he was committed to prison on February
24. In jail he was visited by some of the magistrates and other fellow-Puritans
and under their strong moral suasion admitted to being guilty of the suspected
crime but almost immediately revoked his confession. There followed, up to
the ﬁnal day of the drama, a succession of admissions and revocations; but although he impudently and with desperate imprecations ‘‘against himselfe
denyed all thatt he had formerly confessed,’’ witnesses testiﬁed in court to
his former admissions, and their word was accepted as evidence. The court
then ‘‘judged the crime cappitall, and thatt the prisoner and the sow, according
to Levit, 20 and 15, should be put to deathd.’’ And so, on April 8, 1642, ‘‘The
sow being ﬁrst slaine in his sight, he ended his course here. God opening his
mouth before his death, to give him the glory of his rightousness, to the full
satisfaction of all them present, butt in other respects leaving him a terrible example of divine justice and wrath’’ [15,16].
Spencer’s case is a cruel example of injustice. Injustices continue to occur,
although they may not be as extreme as the case of George Spencer. In a recent time, however, when injustice occurs, it trends to favor the aﬄicted or
the malformed. The following case, which was decided in the 1960s, is
a good example of up-to-date injustice. A pregnant woman was involved
in an automobile accident and claimed that the accident was responsible
for her child’s having Down syndrome. In Sinkler v Kneal, ‘‘The plaintiﬀs
ﬁled a complaint containing four counts. In the ﬁrst count plaintiﬀ Nancy
D. Sinkler claimed in her own right $100,000 damages for lacerations and
contusions and shock to her nervous system which resulted in the birth of
a Mongoloid child, Rebecca’’ [17]. The majority opinion of the court pertaining to the third count was reported September 26, 1960, several years after the genetic aspects of Down syndrome had been clariﬁed [18–20]. The
majority opinion clearly devoted its entire discussion to the question of
whether an injured unborn had the right to recover damages in a negligence
suit [17,21].
The majority decision did not address the important question whether the
malformation and the automobile accident involving a pregnant woman
were related. There is no question that the majority decision was accurate
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and sound with regard to the biologic concept that the fetus is a separate
organism. The court, however, was grossly negligent in taking for granted
an etiologic relationship between a pregnant woman’s automobile accident
and the subsequent birth of a child who had Down syndrome. It is obvious
that a turnabout has occurred. The ‘‘malformed’’ oﬀspring and his parents
are no longer accused. On the contrary they have become the plaintiﬀs, seeking recompense and justice for the malformation and the ‘‘injured’’ family,
when, in the eyes of a lawyer and his medical consultants, the mother or infant has been treated negligently during the pregnancy.
Along with cancer, psychiatric illness, and hereditary diseases, reproductive problems have been viewed throughout history as diseases of aﬄiction
(Fig. 1). Inherent in the reactions of most cultures is that these diseases represent punishments for misdeeds [12–14]. Regardless of the irrationality of
this viewpoint, these feelings do exist. Ancient Babylonian writings recount
tales of mothers being put to death because they delivered malformed infants. As previously cited, George Spencer was slain by the Puritans in
New Haven in the seventeenth century, having been convicted of fathering
a cyclopean pig because the Puritans were unable to diﬀerentiate between
George Spencer’s cataract and the malformed pig’s cloudy cornea [21]. In
modern times, some individuals who have reproductive problems reverse
the historical perspective and blame others for the occurrence of their congenital malformations, infertility, abortions, and hereditary diseases [22].
They place the responsibility for their illness on environmental agents dispensed by their health care provider or used by their employer.
Reproductive problems alarm the public, the press, and some scientists to
a greater degree than most other diseases. In fact, severely malformed children are disquieting to health care providers, especially those not experienced in dealing with these problems. No physician is comfortable
informing a family that their child has been born without arms and legs.
The objective evaluation of environmental causes of reproductive diseases
is clouded by the emotional climate that surrounds these diseases, resulting
υ Through

the ages:
Cancer
Mental retardation
Psychiatric illness
Hereditary diseases
Congenital malformations

Spontaneous Abortions
Fig. 1. Through the ages these diseases have been interpreted or considered by multiple cultures
to be stigmatizing; punishments for misdeeds or sins. In modern times, environmental factors
are thought to cause these diseases. Converting the guilt of the past into anger that is projected
on others in our society sometimes leads to litigation.
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in the expression of partisan positions that either diminish or magnify the
environmental risks. These nonobjective opinions can be expressed by scientists, the laity, or the press [23]. It is the responsibility of every physician to
be aware of the emotionally charged situation that is created when a family
has a child with a birth defect. The inadvertent comment by a physician,
nurse, resident, or student in attendance at the time of the child’s delivery
can have grave consequences for the physician and the family. Comments
such as, ‘‘Oh, you had an X-ray during your pregnancy,’’ or ‘‘You did
not tell me that you were prescribed tetracycline while you were pregnant,’’
can direct the patient’s family to an attorney rather than to a teratology or
genetic counselor.

How serious is the malpractice situation?
From the perspective of the perinatologist and the obstetrician, the answer is, ‘‘Very serious.’’
There were more than 210,000 closed claims reported to the data-sharing
project of the Physician Insurer Association of America during a recent 20year period [24]. Of the 28 medical specialties, the highest percentage of
closed claims in which indemnity payments were made was ascribed to dentists, at 43%, with an average claim payment of $15,000.00. Obstetricians
had the second-highest percentage of indemnity payments, at 36%, but
the average claim payment was $110,000.00. Pediatricians account for
2.97% of these claims, making pediatrics the tenth among the 28 specialties
in terms of the number of closed claims and sixteenth in terms of indemnity
payment rate (28.13%). These ﬁgures include both settlements and lost lawsuits. The average cost to try a malpractice lawsuit is greater than the average settlement costs. Many nonmeritorious lawsuits are settled because it is
cheaper for the insurance company to settle a case than to enter the courtroom and win.
Being a defendant in a malpractice lawsuit is an enervating, anxiety-provoking, time-consuming, and lengthy process. Some of these lawsuits last
for years before they reach their conclusion [25]. The burden of the lawsuit
can aﬀect collegial relationships and the obstetrician’s family life as well as
his or her ability to carry out the practice of medicine. In many instances,
the defendant feels like he or she is being treated like a criminal. Accusations
and badgering in the deposition and even the courtroom can be distressing.
It is an experience that every physician would rather avoid.

How does the obstetric community avoid product liability litigation?
The simple answer would be that the obstetrician can avoid product liability litigation by not prescribing drugs that have reproductive risks for the
mother or developmental risks for the developing embryo or fetus. Table 2
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Table 2
Proven human teratogens or embryotoxins: drugs, chemicals, milieus, and physical agents that
have resulted in human congenital malformations
Reproductive toxin

Alleged eﬀects

Aminopterin,
methotrexate

Growth retardation, microcephaly,
meningomyelocele, mental retardation,
hydrocephalus, and cleft palate
Masculinization of the developing fetus can
occur from androgens and high doses of
some male-derived progestins
Fetal hypotension syndrome in second and
third trimester resulting in fetal kidney
hypoperfusion and anuria,
oligohydramnios, pulmonary hypoplasia,
and cranial bone hypoplasia. No eﬀect in
the ﬁrst trimester.
Recent publications have implicated some of
the SSRIs administered in the last trimester
with postnatal neurobehavioral eﬀects that
are transient and whose long-term eﬀects
have not been determined. First-trimester
exposures to some SSRIs have been
reported to increase the risk of some
congenital malformations, predominantly
congenital heart disease. The results have
not been consistent, but warnings have
been issued.
Isoniazid and paraaminosalicylic acid have an
increased risk for some CNS abnormalities.
Moderate caﬀeine exposure is not associated
with birth defects; high exposures are
associated with an increased risk of
abortion but the data are inconsistent.
Vascular disruption malformations (ie,
limb-reduction defects)
Fetal goiter

Androgens

Angiotensin-converting
enzyme inhibitors

Antidepressants

Antituberculous therapy
Caﬀeine

Chorionic villous sampling
Cobalt in hematemic
multivitamins
Cocaine
Corticosteroids

Vascular disruptive type malformations in
very low incidence; pregnancy loss
High exposures administered systemically
have a low risk for cleft palate in some
studies, but the epidemiologic studies are
not consistent.
(continued on next page)
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Table 2 (continued )
Reproductive toxin

Alleged eﬀects

Cyclophosphamide and other
chemotherapeutic agents and
immunosuppressive agents (eg,
cyclosporine, leﬂunomide)

Many chemotherapeutic agents used to treat
cancer have a theoretical risk for producing
malformations in the fetus when
administered to pregnant women, especially
because most of these drugs are teratogenic
in animals, but the clinical data are not
consistent. Many of these drugs have not
been shown to be teratogenic, but the
numbers of cases in the studies are small.
Caution is the byword.
Administration during pregnancy produces
genital abnormalities, adenosis, and clear
cell adenocarcinoma of vagina in
adolescents. The last has a risk of 1:1000 to
1:10;000, but the other eﬀects, such as
adenosis, can be quite high.
Fetal alcohol syndrome consists of
microcephaly, mental retardation, growth
retardation, typical facial
dysmorphogenesis, abnormal ears, small
palpebral ﬁssures.
Radiation exposure above a threshold of 20
rad (0.2 Gy) can increase the risk for some
fetal eﬀects such as microcephaly or growth
retardation, but the threshold for mental
retardation is higher.
Insulin shock therapy, when administered to
pregnant women, resulted in microcephaly,
mental retardation.
Chronic usage for the treatment of manicdepressive illness has an increased risk for
Ebstein’s anomaly and other
malformations, but the risk seems to be
very low.
This drug’s promotion of hair growth was
discovered because administration during
pregnancy resulted in hirsutism in
newborns.
Aplasia cutis has been reported to be
increased in mothers administered this drug
during pregnancya.
Fetal intestinal atresia, hemolytic anemia, and
jaundice in neonatal period. This procedure
is no longer used to identify one twin.
A low incidence of vascular disruptive
phenomenon, such as limb-reduction
defects and Mobius syndrome, has been
reported in pregnancies in which this drug
was used to induce an abortion.

Diethylstilbestrol

Ethyl alcohol

Ionizing radiation

Insulin shock therapy

Lithium therapy

Minoxidil

Methimazole

Methylene blue
intra-amniotic instillation
Misoprostol

(continued on next page)
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Table 2 (continued )
Reproductive toxin

Alleged eﬀects

Penicillamine (D-penicillamine)

This drug results in the physical eﬀects
referred to as ‘‘lathyrism,’’ the results of
poisoning by the seeds of the genus
Lathyrus. It causes collagen disruption,
cutis laxa, and hyperﬂexibility of joints.
The condition seems to be reversible, and
the risk is low.
Very high doses of androgen
hormone–derived progestins can produce
masculinization. Many drugs with
progestational activity do not have
masculinizing potential. None of these
drugs have the potential for producing
nongenital malformations.
This drug and other antithyroid medications
administered during pregnancy can result
in an infant born with a goiter.
Tissue- and organ-speciﬁc damage depends
on the radioisotope element and
distribution (ie, high doses of Iodine-131
administered to a pregnant woman can
cause fetal thyroid hypoplasia after the
eighth week of development).
Systemic retinoic acid, isotretinoin, and
etretinate can cause increased risk of CNS,
cardioaortic, ear, and clefting defects such
as mMicrotia, anotia, thymic aplasia, other
branchial arch and aortic arch
abnormalities, and certain congenital heart
malformations.
Topical administration is very unlikely to
have teratogenic potential, because
teratogenic serum levels cannot be attained
by topical exposure to retinoids.
Streptomycin and a group of ototoxic drugs
can aﬀect the eighth nerve and interfere
with hearing; it is a relatively low-risk
phenomenon. Children are less sensitive
than adults to the ototoxic eﬀects of these
drugs.
These drugs can produce hemolysis in some
subpopulations of fetuses.
This drug produces bone and teeth staining, it
does not increase the risk of any other
malformations.

Progestin therapy

Propylthiouracil

Radioactive isotopes

Retinoids

Retinoids, topical

Streptomycin

Sulfa drugs and vitamin K
Tetracycline

(continued on next page)
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Table 2 (continued )
Reproductive toxin

Alleged eﬀects

Thalidomide

This drug results in an increased incidence of
deafness, anotia, preaxial limb-reduction
defects, phocomelia, ventricular septal
defects, and gastrointestinal atresias. The
susceptible period is from the
twenty-second to the thirty-sixth day
after conception.
This drug was used frequently to treat urinary
tract infections and has been linked to an
increased incidence of neural tube defects.
The risk is not high, but it is biologically
plausible because of the drug’s eﬀect on
lowering folic acid levels, which has
resulted in neurologic symptoms in adults
taking this drug.
The malformations reported with the
retinoids have been reported with very high
doses of vitamin A (retinol). Dosages to
produce birth defects would have to be in
excess of 25,000 to 50,000 units/d.
Large doses given in vitamin D prophylaxis
may be involved in the etiology of
supravalvular aortic stenosis, elﬁn faces,
and mental retardation.
Early exposure during pregnancy can result in
nasal hypoplasia, stippling of secondary
epiphysis, intrauterine growth retardation.
Central nervous system malformations can
occur in late pregnancy exposure because of
bleeding.

Trimethorpin

Vitamin A

Vitamin Da

Warfarin and warfarin
derivatives

Anticonvulsants
Diphenylhydantoin

Trimethadione and
paramethadione

Valproic acid

Carbamazepine

Treatment of convulsive disorders increases
the risk of the fetal hydantoin syndrome,
consisting of facial dysmorphology, cleft
palate, ventricular septal defect, and
growth and mental retardation.
Treatment of convulsive disorders with these
drugs increases the risk of characteristic
facial dysmorphology, mental retardation,
V-shaped eyebrows, low-set ears with
anteriorly folded helix, high-arched palate,
irregular teeth, CNS anomalies, and severe
developmental delay.
Treatment of convulsive disorders with this
drug increases the risk of spina biﬁda, facial
dysmorphology, and autism.
Treatment of convulsive disorders with this
drug increases the risk facial
dysmorphology.
(continued on next page)
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Table 2 (continued )
Reproductive toxin
Chemicals
Carbon monoxide poisoning

Lead

Gasoline addiction embryopathy
Methyl mercury

Polychlorinated biphenyls

Toluene addiction embryopathy
Embryonic and fetal infections
Cytomegalovirus infection
Rubella
Herpes simplex
HIV
Parvovirus infection, B19
Syphilis

Toxoplasmosis

Alleged eﬀects
Central nervous system damage has been
reported with very high exposures, but the
risk seems to be lowa.
Very high exposures can cause pregnancy
loss; intrauterine teratogenesis is not
established at very low exposures below
20 mg/% in the serum of pregnant mothers.
Facial dysmorphology, mental retardation
Minamata disease consists of cerebral palsy,
microcephaly, mental retardation,
blindness, and cerebellum hypoplasia.
Other epidemics have occurred from
adulteration of wheat with mercurycontaining chemicals that are used to
prevent grain spoilage. Present
environmental levels of mercury are
unlikely to represent a teratogenic risk, but
reducing or limiting the consumption of
carnivorous ﬁsh has been suggested to
avoid exceeding the maximum permissible
exposure recommended by the
Environmental Protection Agency, an
exposure level far below the level at which
the toxic eﬀects of mercury are seen
Poisoning has occurred from adulteration of
food products (‘‘ Cola-colored babies,’’
CNS eﬀects, pigmentation of gums, nails,
teeth, and groin; hypoplastic deformed
nails; intrauterine growth retardation;
abnormal skull calciﬁcation). The threshold
exposure has not been determined, but it is
unlikely to be teratogenic at the present
environmental exposures.
Facial dysmorphology, mental retardation
Retinopathy, CNS calciﬁcation,
microcephaly, mental retardation
Deafness, congenital heart disease,
microcephaly, cataracts, mental retardation
Fetal infection, liver disease, death
Perinatal HIV infection
Stillbirth, hydrops
Maculopapular rash, hepatosplenomegaly,
deformed nails, osteochondritis at joints of
extremities, congenital neurosyphilis,
abnormal epiphyses, chorioretinitis
Hydrocephaly, microphthalmia,
chorioretinitis, mental retardation
(continued on next page)
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Table 2 (continued )
Reproductive toxin
Varicella zoster

Venezuelan equine
encephalitis
Maternal disease states
Corticosteroid-secreting
endocrinopathy

Iodine deﬁciency
Intrauterine problems
of constraint and vascular
disruption

Maternal androgen
endocrinopathy (adrenal tumors)
Maternal diabetes
Maternal folic acid in
reduced amounts
Maternal phenylketonuria

Maternal starvation

Tobacco smoking
Zinc deﬁciencya

Alleged eﬀects
Skin and muscle defects; intrauterine growth
retardation; limb reduction defects, CNS
damage (very low increased risk)
Hydranencephaly; microphthalmia;
destructive CNS lesions; luxation of hip
Mothers who have Cushing’s disease can have
infants with hyperadrenocortism, but
anatomic malformations do not seem to be
increased.
Can result in embryonic goiter and mental
retardation
These defects are more common in multiplebirth pregnancies, pregnancies with
anatomic defects of the uterus, placental
emboli, or amniotic bands. Possible birth
defects include club feet, limb-reduction
defects, aplasia cutis, cranial asymmetry,
external ear malformations, midline closure
defects, cleft palate and muscle aplasia,
cleft lip, omphalocele, and encephalocele)
Masculinization
Caudal and femoral hypoplasia, transposition
of great vessels, and other malformations
An increased incidence of neural tube defects
Abortion, microcephaly, and mental
retardation; very high risk in untreated
patients
Intrauterine growth restriction, abortion,
neural tube defects (Dutch famine
experience)
Abortion, intrauterine growth restriction,
stillbirth
Neural tube defectsa

Abbreviation: CNS, central nervous system.
a
Controversial.

describes the known agents that increase reproductive and developmental
risks [9–11,26]. Unfortunately, the situation is not so straightforward. In
many lawsuits alleging that congenital malformations were the result of
a drug exposure, the allegation was incorrect (Box 1).
Progestational drugs
The largest number of product liability congenital malformation lawsuits
that involved the obstetric community erroneously alleged that progestational
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Box 1. Agents erroneously alleged to have caused human
malformations
Bendectin: Alleged to cause numerous types of birth defects
including limb-reduction defects, heart malformations, and
many other malformations
Diagnostic ultrasonography: No significant hyperthermia,
therefore no reproductive effects
Electromagnetic fields: Alleged to cause abortion, cancer, and
birth defects
Progestational drugs: Alleged to cause numerous types of
nongenital birth defects, including limb-reduction defects,
heart malformations, and many other malformations

drugs were responsible for the occurrence of congenital malformations. Frequently, obstetricians were the physician defendants in these cases. Numerous
lawsuits were ﬁled or went to trial involving the progestational drugs, alleging
that they were responsible for the occurrence of congenital heart disease or
limb-reduction defects. In 1977 the Food and Drug Administration (FDA)
placed a black box warning in the label of progestational drugs indicating
that these drugs were associated with the occurrence of congenital heart disease and limb-reduction defects [27]. The warning was placed because several
publications reported an association of progestational drugs and limb-reduction defects, congenital heart disease, and a few other malformations [28–37].
In 1999, 22 years after the black box warning, the FDA removed the warning
[38,39].
Many of the lawsuits were decided in favor of the plaintiﬀs, although the
majority of the lawsuits was decided in favor of the defendants. Irresponsible experts were one of the key contributors the plaintiﬀs’ success in some of
these lawsuits [23]. Obstetricians had to sit through lengthy trials, away from
their family and practice, to defend themselves against an allegation that
was totally erroneous. In 1977 extensive literature indicated that it was
most unlikely that progestational drugs could produce nongenital malformations. In 1981 Wilson and Brent [40] published an extensive review and
analysis of the allegation that progestational drugs could produce nongenital malformations and concluded that the allegation was incorrect. Other
publications were in agreement [41,42], but 22 years elapsed before the
warning was removed [27,39].
Bendectin
Another drug, Bendectin, was prescribed commonly by obstetricians for
the treatment of nausea and vomiting of pregnancy. Thousands of lawsuits

245

AVOIDING REPRODUCTIVE AND DEVELOPMENTAL RISKS

alleged that Bendectin was a teratogen, although Bendectin was the only
drug approved by the FDA for the treatment of nausea and vomiting of
pregnancy. During the 1970s, when Bendectin was used most frequently,
it was prescribed to 30% of pregnant women. There are approximately
4,000,000 births each year in the United States, and the background incidence of major birth defects is 3% (Table 3). Therefore expected background incidence of birth defects would be 120,000; 36,000 newborns who
had congenital anomalies would have been exposed to Bendectin each
year. This prevalence was a bonanza for some plaintiﬀ attorneys, because
a jury might interpret these numbers as representing an epidemic of birth defects. The 36,000 birth defects, however, is exactly the expected background
incidence of birth defects in the Bendectin-exposed group. This medication
was studied extensively, and the allegation had no merit [43–53]. After 20
years of litigation, not a single Bendectin lawsuit was decided on behalf of
the plaintiﬀs [49,50,53]. The medication was removed from the market in
1982, however, because the cost of litigation and negligence insurance was
greater than the gross sales of the medication. The frequency of hospital admissions for nausea and vomiting of pregnancy doubled because Bendectin
was not available, and physicians were reluctant to prescribe any medication
for fear of litigation [51–53]. The numerous negative aspects of the Bendectin saga included (1) the loss of an approved medication for the treatment of
nausea and vomiting of pregnancy, (2) the reluctance of many obstetricians
to use any medication to treat nausea and vomiting of pregnancy, (3) the increase in hospital admissions for the treatment of nausea and vomiting of
pregnancy [52], and (4) the waste of time and expenses to the courts of litigating nonmeritorious lawsuits.
Table 3
Frequency of reproductive risks in the human
Reproductive risk

Frequency

Immunologically and clinically
diagnosed spontaneous
abortions per 106 conceptions
Clinically recognized spontaneous
abortions per 106 pregnancies
Genetic diseases per 106 births
Multifactorial or polygenic
(genetic–environmental interactions)
Dominantly inherited disease
Autosomal and sex-linked genetic disease
Cytogenetic (chromosomal abnormalities)
New mutations
Major congenital malformations per 106 births
Prematurity per 106 births
Fetal growth retardation per 106 births
Stillbirths/106 pregnancies (O20 weeks)
Infertility

350,000

150,000
110,000
90,000
10,000
1200
5000
3000
30,000
40,000
30,000
2000–20,900
7% of couples
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This plethora of litigation did have one major beneﬁcial outcome, however. The Supreme Court rendered the famous Daubert decision as part
of the litigation activities. It permitted jurists to disqualify the testimony
of expert witnesses who used methodologic procedures that are not accepted
and approved by the scientiﬁc community to reach their opinion [48]. The
courts rejected the testimony of several of the plaintiﬀs’ experts involved
in the Daubert decision. This small group of irresponsible medical and scientiﬁc experts contributed negatively to the welfare of the obstetric patients
in the United States [23,49,54].
This review of the progestational drug and Bendectin litigation is a reminder that lawsuits on behalf of a child who has congenital malformations
can be instituted regardless of whether the allegation has scientiﬁc or medical
merit. There are, however, drugs that can harm the developing embryo if administered at a sensitive period of embryonic development and at exposures
high enough to aﬀect the developing embryo or fetus deleteriously. This extensive list of potential embryo toxic agents is listed in Table 2. Box 1 lists
some of the agents that have been involved in litigation that have not
been demonstrated to aﬀect the embryo deleteriously at their acceptable
exposure.
These tables are simply lists that can be misused if one does not pay attention to the importance of timing and dose. For example, thalidomide is
a known and proven teratogen, but if 1 mg were administered during the
sensitive period of development, rather than the usual dose of 50 mg or
greater, there would be no eﬀect on the exposed embryo. Likewise, 50 mg
of thalidomide administered during the sixth month of gestation never
would result in the malformations observed in the typical thalidomide syndrome, because the sensitive period is so limited (Table 4).

Table 4
Developmental stage sensitivity to thalidomide-induced limb-reduction defects in the human
Days from conception
for induction of defects
21–26
22–23
23–34
24–29
24–33
25–31
27–31
28–33
33–36

Limb-reduction defects
Thumb aplasia
Microtia, deafness
Hip dislocation
Amelia, upper limbs
Phocomelia, upper limbs
Preaxial aplasia, upper limbs
Amelia, lower limbs
Preaxial aplasia, lower limbs; phocomelia,
lower limbs; femoral hypoplasia; girdle hypoplasia
Triphalangeal thumb

Data from Brent RL, Holmes LB. Clinical and basic science lessons from the thalidomide tragedy: what have we learned about the causes of limb defects? Teratology 1988;
38:244.
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Anticonvulsants
Another example pertains to the administration of anticonvulsants to
pregnant women because of the frequency with which anticonvulsants are
administered. Diphenylhydantoin, when administered throughout pregnancy, increases the risk of congenital malformations that include facial dysmorphogenesis, microcephaly, decreased cognition, digital hypoplasia, and
ventricular septal defects [55]. These malformations do not occur frequently,
and the physician administering the drugs often is faced with a dilemma as
to whether to continue the medication, reduce the medication, or discontinue use of the anticonvulsant during pregnancy. If, for example, a pregnant
woman is in an automobile accident and sustains a head injury, the consulting neurosurgeon might prescribe one dose of 200 mg of phenytoin. It is
unlikely that this single dose will result in the phenytoin embryopathy.
This future mother, however, has a 3% risk of delivering a baby with congenital malformations. One can imagine how an irresponsible expert might
testify if this mother delivers a child who has congenital malformations.
It is impossible to discuss each of the drugs in Table 2 and describe the
circumstances when the embryo is or is not at risk. Publications dealing
with the subject of teratogenic drugs, chemicals, and physical agents and
the genetic causes of congenital malformations can be useful to clinicians
for evaluating the risks of environmental toxicants [9–11,26,56–62].
Principles of counseling obstetric or perinatology patients about the risks
of pregnancy and the therapy that may be necessary for the patient’s care
Predicting the developmental risks of a pregnancy
Patients frequently ask obstetricians or perinatologists whether a particular preconception or postconception environmental exposure represented
a risk for their developing embryo or fetus. For example, a pregnant patient
might ask whether the chest radiograph that occurred early in her pregnancy
could result in a newborn who had birth defects. The most appropriate answer would be:
A chest radiograph does not expose the embryo to a harmful dose of radiation. The radiation exposure is so low that even the same exposure to your
uterus would not increase your risk for having a child with birth defects.
You must realize, however, that even if you have no personal or family history of reproductive or developmental problems, you began your pregnancy with a 3% risk for birth defects and a 15% risk for miscarriage.

This information should be communicated verbally and also be noted in
the patient’s medical chart. The obstetrician and perinatologist must be
careful not to provide verbal guarantees concerning the outcome of the
pregnancy (eg, ‘‘You have nothing to worry about’’; ‘‘The baby will be
ﬁne.’’). In an eﬀort to quell the patient’s anxiety, the physicians may provide
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misinformation, because physicians cannot prevent the background incidence of developmental problems.
Understanding the principles of teratology to determine
developmental risks
Five principles of teratology are useful for evaluating reproductive and developmental risks. These principles can assist clinicians in evaluating risks and
in determining the signiﬁcance of developmental eﬀects in newborns and children that they have delivered [9–11,26]. When evaluating studies dealing with
the reproductive eﬀects of any environmental agent, important principles
should guide the analysis of human and animal reproductive studies. Paramount to this evaluation is the application of the basic science principles of teratology and developmental biology [9–11,63]. These principles are as follows:
1. Exposure to teratogens follows a toxicologic dose–response curve.
There is a threshold below which no teratogenic eﬀect will be observed;
as the dose of the teratogen is increased, both the severity and frequency
of reproductive eﬀects increase (Table 5).
2. The embryonic stage of exposure is critical in determining what deleterious eﬀects will be produced and whether any of these eﬀects can be
produced by a known teratogen. Some teratogenic eﬀects have a broad
and others have a very narrow period of sensitivity. The most sensitive
Table 5
Stochastic and threshold dose-response relationships of diseases produced by environmental
agents
Relationship Pathology Site

Diseases

Risk

Eﬀect

Stochastic
Damage DNA
phenomena to a
single
cell may
result in
disease

Cancer
mutation

Some risk
exists
at all
dosages;
at low
exposures
the
hypothetical
risk is
below the
spontaneous
risk.
No increased
risk below
the threshold
dose

The incidence of
the disease
increases with
the dose, but
the severity
and nature of
the disease
remain the
same.

Threshold
MultiHigh
Malformation,
phenomena cellular
variation
growth
injury
in etiology, retardation,
aﬀecting
death,
many cells
chemical
and organ
toxicity, and
processes
others

Both the severity
and incidence
of the disease
increase with
dose.

Data from Brent RL. The irresponsible expert witness: a failure of biomedical graduate
education and professional accountability. Pediatrics 1982;70:754–62.
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stage for the induction of mental retardation from ionizing radiation is
from the eighth to the ﬁfteenth week of pregnancy, a lengthy period. Thalidomide’s period of sensitivity is approximately 2 weeks (see Table 4) [64].
3. Even the most potent teratogenic agent cannot produce every
malformation.
4. Most teratogens have a limited group of congenital malformations that
result after exposure during a critical period of embryonic development.
This limited group of malformations is referred to as the syndrome that
describes the agent’s teratogenic eﬀects.
5. Although a group of malformations may suggest the possibility of certain teratogens, they cannot conﬁrm the causal agent deﬁnitively, because some teratogenic syndromes mimic genetic syndromes. On the
other hand, the presence of certain malformations can eliminate the possibility that a particular teratogenic agent was responsible because those
malformations have not been demonstrated to be part of the syndrome
or because the production of that malformation is not biologically plausible for the particular alleged teratogen.
Determining whether an environmental agent has developmental or
reproductive eﬀects at the exposure to which the population is exposed
Evidence supporting or refuting the allegation that an environmental
agent has reproductive or developmental eﬀects at the typical human exposures comes from several areas of investigation [40,49,65]:
1. Consistency. Consistent ﬁndings in a number of epidemiologic studies in
which statistical associations for a spectrum or group of developmental
eﬀects or speciﬁc reproductive eﬀects are found in several studies
2. Secular trend analysis. Secular trend analysis can be used when a large
percentage of the population has been exposed as with the progestational drugs or Bendectin. Changes in exposure caused by a reduction
or cessation of prescribing may or may not alter the incidence of developmental or reproductive eﬀects.
3. Animal reproductive studies. These studies are very useful in determining whether ﬁndings in epidemiologic studies can be conﬁrmed in animal reproductive or developmental studies. Every environmental
agent that has been conﬁrmed to be a human teratogen or reproductive
toxin has been found to be teratogenic in an animal model. When this
conﬁrmation cannot be accomplished, reproductive and developmental
scientists are somewhat concerned about the validity of the causal relationship in the epidemiologic studies.
4. Dose–response relationships and pharmacokinetic studies comparing
human and animal metabolism. One important aspect of modern preclinical testing protocols is that serum and/or tissue levels of the drug
or chemical are determined in both the animal model and in humans.
If reproductive and developmental eﬀects occur in the animal model
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at serum or tissue levels that occur in humans, there should be concern
about the safety of the drug or chemical.
5. Biologic plausibility. This concept is important, because in some instances scientiﬁc considerations can support or refute an allegation of
the reproductive or developmental toxicity. For example, the original epidemiology studies involving progestational drugs reported that epidemiologic studies showed an increased incidence of congenital heart disease
but no increase in the incidence of limb-reduction defects. In other studies there was an increased incidence of limb-reduction defects but no increase in the incidence of congenital heart disease. Those ﬁndings, in
themselves, should have refuted the allegation. Second, progestational
drugs function by attaching to sex steroid receptors. Early in embryonic
development there are no sex steroid receptors in the developing heart
and limb buds. Biologic plausibility involves consideration of
a. Mechanisms
b. Receptor studies
c. Nature of the malformations
d. Mechanism of action
d. Teratology principles
It should be apparent that determining the reproductive risks of an exposure during pregnancy or the origin of a child’s congenital malformations is
not a simple process. It involves a careful analysis of the medical and scientiﬁc literature pertaining to the reproductive toxic eﬀects of exogenous
agents in humans and animals as well as an evaluation of the exposure
and biologic plausibility of an increased risk or a causal connection between
the exposure and a child’s congenital malformation. It also involves a review
of the scientiﬁc literature pertaining to genetic and environmental causes of
the malformations in question. An abridged or superﬁcial evaluation based
on incomplete analyses is not acceptable.
What circumstances stimulate negligence lawsuits?
Certain circumstances seem to stimulate negligence lawsuits in cases of
birth defects [1,23,25,51,66]:
1. A plaintiﬀ who generates sympathy, a defense expert who frequently is
unable to be certain of the cause of the child’s birth defect, and a plaintiﬀ
expert who is certain
2. Neurobehavioral eﬀects, mental retardation, cerebral palsy
3. Miscarriage
3. A high proportion of exposures in the population at risk
4. A scientiﬁc topic that has attracted junk scientists as experts
5. Jurisdictions or geographic areas that are known to favor plaintiﬀ
verdicts
6. A litigation subject that has become attractive to number of law ﬁrms
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7. A new area (drug) for which little data are available and therefore hypotheses without data can be generated
8. Vaccinations given during pregnancy
Clinical situations in which the obstetrician or perinatologist is the primary
provider and the therapy and/or diagnostic tests may represent potential
or hypothetical reproductive and developmental risks
It is impossible to discuss all the medications and pre- and postconception therapies that obstetricians might use to care for their patients. The following is a short list of categories of therapy for which patients have ﬁled
lawsuits alleging that the obstetrician’s or perinatologist’s treatment resulted
in harm to the fetus:
1.
2.
3.
4.
5.
6.
7.
8.
9.

Nausea and vomiting of pregnancy
Treatment of hypertension
Treatment of psychiatric problems (depression, anxiety)
Exposure to various forms of ‘‘radiation’’
Medications and therapy to manage premature labor
Treatment of infections
Immunizations
Diagnostic radiologic studies
Diagnostic ultrasonography

Treating nausea and vomiting of pregnancy
In the 1960s there was an increase in the number of lawsuits involving
malformed children and their families as plaintiﬀs [1]. Many of the lawsuits
involved an antinausea medication, such as meclizine. The ﬁrst meclizine
lawsuit with which I was acquainted occurred in the late 1960s and involved
a child who had ectrodactyly, ectodermal dysplasia, and cleft palatedEEC
syndrome, which is a genetic disease. Scientists from a prestigious university
and the from National Institutes of Health testiﬁed that meclizine caused
this child’s defect; of course, the defect, in fact, was present at the time
of conception, before there was any exposure to the medication.
Bendectin containing doxylamine succinate, dicyclomine, and pyridoxine
was listed as appropriate for the treatment of nausea and vomiting of pregnancy. The FDA approved labeling for Bendectin as the only drug formerly
recommended for the treatment of nausea and vomiting in pregnant women.
Beneﬁts of eﬀective treatment
It is obvious that clinical, psychologic, and social beneﬁts result from any
eﬀective therapy that reduces the symptoms of nausea and vomiting in pregnant women. The beneﬁts include
1. Symptomatic improvement and comfort
2. Preventing the progression of symptoms to necessitate hospitalization
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6.
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Optimal nutrition for mother and fetus
Decreased risk of some pregnancy complications
Psychologic beneﬁts
Decrease absenteeism for working mothers
Decreased diﬃculty in managing the home and family

Medical risks of therapeutic intervention
The medical risks of any therapy have two implications. The ﬁrst is that
the therapy may be unacceptable to the patient or may represent a medical
risk that is unacceptable to the physician and the patient. In other circumstances the theoretic risk of a new therapy could be more signiﬁcant than the
beneﬁt of relieving the nausea and vomiting. Some of these risks, if they occur, could lead to litigation. The most serious medicolegal risk is the occurrence of embryonic and fetal malformations.
Legal risks of therapeutic intervention
Because many of the therapies for nausea and vomiting of pregnancy are
relatively new, there are minimal data on which to base an evaluation of the
risk of reproductive eﬀects. Unfortunately, attorneys can be creative in generating hypotheses and obtaining witnesses who are willing to support hypotheses that implicate the therapy as having teratogenic potential [23,25].
Even when therapies such as acupressure, hypnosis, psychotherapy, or psychologic conditioning seem to be very unlikely to harm the fetus, that unlikelihood does not prevent a lawsuit from being initiated if a severely
malformed fetus results from a pregnancy. Therefore, the best protection
for the patient, the physician, the manufacturer of a drug, or the developer
of a therapeutic technique is to have abundant data that indicate that the
therapy has no measurable harmful eﬀects on the developing embryo or fetus or on pregnant women. Unfortunately, only one therapy that ﬁts these
criteria, and that is Bendectin (10 mg each of doxylamine succinate and pyridoxine). Twelve cohort studies and numerous case-control studies, involving more than 13,000 patients, indicate that Bendectin does not represent
a measurable risk to the developing mother or fetus. Furthermore, the animal studies and in vitro studies support this conclusion [49,50,53]. No other
treatment of nausea and vomiting during pregnancy has the demonstrated
low-risk record of Bendectin. Unfortunately, this medication is no longer
sold in the United States, but it is sold in Canada under a proprietary
name [67]. It has the same constituents as Bendectin (10 mg of pyridoxine
and 10 mg of doxylamine succinate).
In 1999 the FDA published a statement in the Federal Register that summarizes the FDA’s opinion on the lack of teratogenicity of Bendectin [68].
In summary:
The Food and Drug Administration has determined that the drug product
Bendectin, a tablet composed of pyridoxine hydrochloride, 10 mg, and doxylamine succinate, 10 mg, for the prevention of nausea during pregnancy,
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was not withdrawn from sale for reasons of safety or eﬀectiveness. This determination will permit FDA to approve abbreviated new drug applications
for the combination product pyridoxine hydrochloride, 10 mg, and doxylamine succinate, 10 mg, tablets.

Treatment of hypertension during pregnancy
Toxemia of pregnancy, renal hypertension, lupus hypertension, idiopathic ‘‘essential’’ hypertension, and other causes of hypertension represent
serious medical problems during pregnancy. Fortunately, there are numerous excellent medications to treat high blood pressure. Two classes of
medications, however, have serious, deleterious eﬀects on fetal development
[69–72]. Fetal exposure during the second and third trimester to angiotensinconverting enzyme inhibitors or the angiotensin II receptor blockers may
produce severe fetal hypotension, oligohydramnios, pulmonary hypoplasia,
fetal and neonatal renal failure, and decreased calciﬁcation of the skull. If
the fetus survives, death can occur postnatally from renal or pulmonary failure. Some children survive after renal transplantation. Animal studies support the clinical impression that the second and third trimester are the
vulnerable period when the drugs do their damage and that exposure during
early organogenesis does not seem to have any detrimental eﬀect from. A
recent article by Cooper and colleagues [73] indicates that there is an increased risk of congenital malformations with ﬁrst trimester exposures,
but the animal studies and other epidemiologic studies do not support these
ﬁndings.
Treatment of psychiatric problems (depression, anxiety)
during pregnancy
Many drugs that are used for the treatment of psychiatric disorders demonstrate transient behavioral eﬀects in newborns whose mothers received
these medications before delivery of the infant. Transient irritability, jitteriness, and depression may be manifested, depending on the primary eﬀects
of the medication. Very few of these drugs have been reported to be associated with reproductive or developmental eﬀects, although some of the anticonvulsants that have psychopharmacologic therapeutic eﬀects (eg,
diphenylhydantoin, valproic acid, carbamazepine, phenobarbital) have
been associated with an increased risk of birth defects (see Table 2).
Recently the selective serotonin receptor reductase inhibitors (SSRIs)
have been studied for ﬁrst-trimester teratogenic eﬀects, and paroxetine
was reported to be associated with an increased risk of congenital heart disease [74,75]. These ﬁndings have not been consistent, however, because there
are studies that do not conﬁrm these ﬁndings [76,77]. The few animal studies
that have been reported do not ﬁnd teratogenic eﬀects [78]. The increased
teratogenic risks following ﬁrst-trimester exposure to SSRIs has yet to be
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resolved, although the FDA and the companies involved have issued warnings about the potential teratogenicity of SSRIs.
Radiation exposures
The public and some health care providers have concerns about new diagnostic radiation modalities using radiographs and radionuclides. Some
physicians and many patients assume that these new procedures involve
much higher exposures and much higher risks. It is important that all the
new procedures and their embryonic risks be placed in proper perspective.
These procedures include
CT scans and positron emission tomograph scans
MRI studies (Many patients believe that X-rays are involved in these
studies, which is not true. The electromagnetic ﬁelds used in MRI studies are non-ionizing forms of radiation.)
Diagnostic scans using radionuclides for studying the location of a pulmonary embolus, the presence of gallbladder disease, cardiac perfusion, cardiac stress test, areas of bone inﬂammation or injury, thyroid function,
liver function, renal perfusion, lung perfusion, and other conditions
There are misconceptions concerning the reproductive and developmental risks of low exposures of ionizing radiation from occupational exposures
and airplane travel, especially the magnitude of the risk from solar ﬂares.
Health care providers who work in medical or research ﬁelds have exaggerated concerns about the reproductive or developmental risks of their onthe-job exposures. Among the most common concerns are those of dental
technicians who perform the dental radiographic examinations in a dentist’s
oﬃce and nurses and operating room assistants who are in proximity to
ﬂuoroscopes or brachytherapy procedures in the operating room.
Pregnant patients receiving radiation therapy for the treatment of cancer
or other serious diseases are in a special category. If the fetus is in the therapeutic beam, it is likely that the treatment will be harmful to the developing
embryo. The developmental risks also can be increased in pregnant women
receiving therapeutic doses of radionuclides.
Concern about the risk of infertility or genetic disease in their children from
preconception radiation exposure of the ovaries or testicles has been increasing among patients contacting the Health Physics Ask the Expert Website.
The public and some health care providers have old and new concerns
about the risks of harm to the embryo from non-ionizing ‘‘radiation’’ because
of misconceptions about the risks that can be ascribed to the many forms of
non-ionizing radiation. Although addressing these issues may seem unnecessary, these exposures can generate as much concern and anxiety as the
exposures to ionizing radiation that do represent a real risk to the embryo.
These concerns have been communicated frequently to the Health Physics
Society Website, Ask The Expert [66,79–82]. Matters of concern include
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Diagnostic ultrasound procedures that expose the embryo or expose
other parts of the body of a pregnant woman
Exposure to electromagnetic ﬁelds from power lines, house appliances,
electric commuter trains
Exposure to or proximity to microwave communication antennae for ﬁre
departments, police departments, ambulance services, or cellular telephone communications
Exposure to personal cellular telephones (birth defects in their embryo
and cancer in themselves)
Visiting a tanning salon while pregnant
Laser hair removal from the abdomen or thigh of pregnant patients
Use of an ultrasound sonicator for preparing tissue or cleaning jewelry
Use of a hair dryer, computer, cellular telephone, or microwave oven
Working in an oﬃce or other site in proximity to a microwave dish
Walking through a metal detector scanner at any security monitoring site
The possibility that a suitcase and its contents will become radioactive after passing through an airport X-ray scanner
Exposure to ultraviolet light for treating certain skin disease
Exposure to intense light and dermatologic chemicals for the treatment of
acne
Eating food that has been sterilized by exposure to ionizing radiation
Other concerns of pregnant women in regard to radiation exposure include inadvertently being in a room when a radiograph was taken and being
near a patient who has received external radiation therapy or who has been
given a radionuclide for diagnostic or therapeutic purposes.
One must realize that families have grave concerns about having a child
who has a birth defect, having a miscarriage, or having a child who has neurologic problems, mental retardation, or cancer following ‘‘radiation’’ exposures. Counselors must address these fears, even though many of them have
no scientiﬁc basis. Discussion of all these matters in a compassionate and
erudite manner can be of great beneﬁt to concerned parents [66,81,82].

Clinical situations when a consultant is the primary prescriber
of medications or therapies for diseases for which the obstetrician
or perinatologist is not an expert
A proportion of obstetric and perinatology patients have medical problems that require special skills and training. Many of these special patients
require medical care beyond the prenatal care and delivery services of an obstetrician or perinatologist. Many of these patients may need special medications, and it is important to review these medications with the medical
consultant to make certain that the patient has been informed of any reproductive or developmental risks associated with these medications and
whether alternative medications can be selected that do not reproductive
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or developmental risks. The patient’s medical record should note the interaction with the consultant concerning the medications and that the information has been shared with the patient. Some perinatologists have been
trained to care for diabetic pregnant patients or patients who have other
complicated medical problems. It is advantageous for the perinatologist
who is caring for pregnant patients who have complicated medical diseases
to require that the patient’s medical care be provided by the medical consultant. Diseases that necessitate the use of medications that may have reproductive or developmental risks include diabetes, malignancies, autoimmune
disease, some infections, asthma or hyperactive airway disease, and any
form of pulmonary or cardiac decompensation.
The perinatologist or obstetrician may not be an expert in many of these
complicated medical diseases but can be very helpful to the medical consultant in selecting medications that are necessary for the patient that have either no increased risk or the least increased risk for reproductive or
developmental problems.

How should a physician in respond to a citation that he or she is being sued
for malpractice?
I have been a defense expert for many obstetricians, and on one occasion
I was a plaintiﬀ expert in an egregious case of malpractice that was settled
before the trial began. I have the following suggestions for the defendants:
1. Immediately notify your insurance carrier, the hospital (if it is a hospital
case), your partners, and appropriate members of your family.
2. Recognize that any competent attorney can study the medical aspects of
the case and know more than you do at the time of the depositions and
trial. Therefore, the three most important aspects of being a defendant
are ‘‘preparation, preparation, and preparation.’’
3. Make certain that you have an excellent attorney and law ﬁrm. You
have the right to request new counsel if you detect delays and
incompetence.
4. Make certain that you have the best expert witnesses with absolutely no
academic or ethical skeletons in their closet.
5. Do not:
A. Go to the record room on the day you receive your citation and sign
out the chart. You can look at your oﬃce records, but stay away
from the record room until you have competent legal representation
who will obtain the records in a proper manner.
B. Call the plaintiﬀ’s attorney, even if you are friends or belong to the
same organization or club.
C. Call the plaintiﬀ. Inform the patient that you are transferring her records to another physician. Your lawyer should supervise this
correspondence.
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D. Contact other defendants or potential defendants in the case without
advice from your attorney. If contact is made, your attorney should
be present.
6. Be prepared for a lengthy process that is enervating, exhausting, and
possibly anxiety-provoking. You will need the support of family, partners, attorney, and noninvolved colleagues.
What measures can scientists and physicians initiate to diminish
the litigation epidemic?
Bendectin litigation is the prototype of nonmeritorious litigation, and the
issues involved explain in part the epidemic of litigation brought before
juries in this country. A lawsuit is ﬁled because it may be won, regardless
of whether it has merit [1,25,66,82]. A few changes could reduce the negligence litigation crisis and the excessive amount of nonmeritorious litigation
in the United States.
The ﬁrst suggestion is to eliminate the contingency-fee system for attorney compensation, a system that is practically nonexistent in the rest of
the world. It is unlikely that this suggestion is going to be adopted for
a long time in the United States, because the members of the law profession
dominate the state and federal legislatures and have an undue inﬂuence on
a signiﬁcant proportion of the legislators [1,25].
The second suggestion is to put a cap on the size of the awards, especially
on punitive damages. This suggestion has reduced litigation in some venues,
but it will not solve the crisis.
The third suggestion is to eliminate the use of plaintiﬀ and defense expert
witnesses and rely on expert scientiﬁc panels that are ‘‘friends of the court.’’
I discussed this matter many years ago [1]. I found out, however, that many
of the plaintiﬀ and defense attorneys want to use experts whom they select.
Attorneys do not want a panel of court-assigned experts.
The fourth and most important suggestion is to have the loser pay the
court costs. This measure would reduce dramatically the number of nonmeritorious lawsuits. It would discourage plaintiﬀs from ﬁling nonmeritorious
lawsuits and would encourage insurance companies to defend their clients
rather than settle the nonmeritorious lawsuits, which is one of the large
item costs in handling malpractice lawsuits. Assessing the court costs to
the loser would change in the number of negligence lawsuits radically.
As physicians and scientists, we must recognize that the only area of litigation over which science and medicine can have legitimate control is in the performance of expert witnesses. Most nonmeritorious cases would not proceed if
the attorneys could not ﬁnd a physician or scientist who is willing to say that
a nonmeritorious case has merit. Therefore, although we may be displeased
with some attorneys and may blame them for the epidemic of litigation, the
fact is that unscrupulous scientists and physicians have an important role in
promoting nonmeritorious actions. Because we are not able to modernize
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the legal system, our best initiative is to alter drastically the activities of the irresponsible expert by raising the quality of expert-witness testimony
[23,54,66,82]. We must strengthen the guidelines of universities and professional organizations in the United States to train and encourage scientists
and physicians to perform as scholars and to monitor their contributions to
the courts. If they do not provide competent and scholarly testimony, they
should be criticized or expelled by their universities or their professional scientiﬁc and medical organizations.
Summary
Although some aspects of this discussion may seem to be critical of the
legal profession, it is important to place this criticism into perspective. Physicians, as a group, tend to be hypercritical of the legal profession because of
the escalation of malpractice litigation and malpractice insurance premiums.
Recommendations from the medical community to modify the law to reduce
the frequency of nonmeritorious litigation and the size of the awards have
been minimally successful, primarily because lawyers dominate the legislatures. Furthermore, many attempts by physicians to change the law are naive. My suggestions in the past have urged the medical community to focus
their attention on junk scientists and their junk science, because they are
problems that emanate from the medical community, over which physicians
should have some authority [1,23,25].
More importantly, we should respect the importance and accomplishments of the legal profession and admire its accomplishments, because it
is the foundation of any thriving democracy. Without the law, we could
never have rid ourselves of a sitting president or protect all rights bestowed
on individuals in our Constitution. A very small percentage of attorneys exploiting the power of the law to their own advantage does not mean that the
legal system must be replaced or eliminated. It is to everyone’s advantage to
have a functioning legal system with its beneﬁts and risks. Remember that
many nonmeritorious lawsuits could not proceed without the testimony of
a junk scientist who appears before a judge and testiﬁes that the case has
merit. Many of these junk scientists are obstetricians and pediatricians as
well as other members of the clinical and scientiﬁc community [49–51].
Will the situation improve? I cannot predict the future of malpractice litigation, but we are not doing our job by allowing irresponsible expert witnesses to participate in matters of litigation without being censured by
their university or professional organizations [47,49–51].
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